

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 August 2024 (15.08.2024)



(10) International Publication Number
WO 2024/168010 A3

(51) International Patent Classification:
C12N 15/11 (2006.01) A61K 31/7125 (2006.01)
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2024/014761

(22) International Filing Date:
07 February 2024 (07.02.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/444,375 09 February 2023 (09.02.2023) US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.**
[US/US]; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, MA 02142 (US).

(72) Inventors: **ZLATEV, Ivan**; 675 West Kendall Street, Henri
A. Termeer Square, Cambridge, MA 02142 (US). **CAS-
TORENO, Adam**; 675 West Kendall Street, Henri A. Ter-
meer Square, Cambridge, MA 02142 (US). **JADHAV, Vas-
ant, R.**; 675 West Kendall Street, Henri A. Termeer Square,
Cambridge, MA 02142 (US). **MAIER, Martin, A.**; 675
West Kendall Street, Henri A. Termeer Square, Cambridge,
MA 02142 (US). **KASPER, Anne**; 675 West Kendall
Street, Henri A. Termeer Square, Cambridge, MA 02142
(US). **TU, Ho, Chou**; 675 West Kendall Street, Henri A.
Termeer Square, Cambridge, MA 02142 (US). **FOSTER,
Donald**; 675 West Kendall Street, Henri A. Termeer Square,
Cambridge, MA 02142 (US).

(74) Agent: **NAGLE, Deborah, L.** et al.; McCarter & English,
LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:
21 November 2024 (21.11.2024)

WO 2024/168010 A3

(54) Title: REVERSIR MOLECULES AND METHODS OF USE THEREOF

(57) Abstract: The present invention provides REVERSIR compounds which inhibit the RNAi interference activity of dsRNA agents comprising a thermally destabilizing nucleotide modification in the antisense strand, and methods of use thereof.